Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

ABSTRACT:

Objective

We characterized associations between central nervous system (CNS) adverse events and brain neurotransmitter transporter/receptor genomics among participants randomized to efavirenz-containing regimens in AIDS Clinical Trials Group studies in the USA.

Participants and methods

Four clinical trials randomly assigned treatment-naive participants to efavirenz-containing regimens. Genome-wide genotype and PrediXcan were used to infer gene expression levels in tissues including 10 brain regions. Multivariable regression models stratified by race/ethnicity were adjusted for CYP2B6/CYP2A6 genotypes that predict plasma efavirenz exposure, age, and sex. Combined analyses also adjusted for genetic ancestry.

Results

Analyses included 167 cases with grade 2 or greater ef

SUBMITTER: Haas DW 

PROVIDER: S-EPMC6010221 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature